| Literature DB >> 30666641 |
Karen T Chang, Mulenga Mukanu, Ben Bellows, Waqas Hameed, Amanda M Kalamar, Karen A Grépin, Xaher Gul, Nirali M Chakraborty.
Abstract
The Method Information Index (MII) is calculated from contraceptive users' responses to questions regarding counseling content-whether they were informed about methods other than the one they received, told about method-specific side effects, and advised what to do if they experienced side effects. The MII is increasingly reported in national surveys and used to track program performance, but little is known about its properties. Using additional questions, we assessed the consistency between responses and the method received in a prospective, multicountry study. We employed two definitions of consistency: (1) presence of any concordant response, and (2) absence of discordant responses. Consistency was high when asking whether users were informed about other methods and what to do about side effects. Responses were least consistent when asking whether side effects were mentioned. Adjusting for inconsistency, scores were up to 50 percent and 30 percent lower in Pakistan and Uganda, respectively, compared to unadjusted MII scores. Additional questions facilitated better understanding of counseling quality.Entities:
Mesh:
Year: 2019 PMID: 30666641 PMCID: PMC6590213 DOI: 10.1111/sifp.12081
Source DB: PubMed Journal: Stud Fam Plann ISSN: 0039-3665
Characteristics of clients by country
| Pakistan (N = 813) | Uganda (N = 1,185) | |||
|---|---|---|---|---|
| n | % | n | % | |
|
| ||||
| IUD | 350 | 43.1 | 276 | 23.3 |
| Implant | — | — | 431 | 36.4 |
| Injectable | 199 | 24.5 | 335 | 28.3 |
| Pill | 149 | 18.3 | 122 | 10.3 |
| Other ST method | 115 | 14.1 | 21 | 1.8 |
|
| ||||
| First‐time user | 294 | 36.2 | 314 | 26.5 |
| Lapsed adopter | 42 | 5.2 | 177 | 14.9 |
| Method‐switcher | 477 | 58.7 | 694 | 58.6 |
|
| ||||
| 15–24 | 125 | 15.4 | 475 | 40.1 |
| 25–34 | 443 | 54.5 | 531 | 44.8 |
| 35–49 | 245 | 30.1 | 179 | 15.1 |
|
| ||||
| None (never went to school) | 468 | 57.6 | 29 | 2.4 |
| Primary | 145 | 17.8 | 401 | 33.8 |
| Secondary | 151 | 18.6 | 595 | 50.2 |
| Beyond secondary | 49 | 6.0 | 160 | 13.5 |
|
| ||||
| Nulliparous | 1 | 0.1 | 112 | 9.5 |
| Primiparous | 97 | 11.9 | 255 | 21.5 |
| 2–3 live births | 317 | 39.0 | 448 | 37.8 |
| 4–5 live births | 235 | 28.9 | 239 | 20.2 |
| 6 or more live births | 163 | 20.0 | 131 | 11.1 |
|
| ||||
| 1 (poorest) | 54 | 6.6 | 21 | 1.8 |
| 2 | 126 | 15.5 | 46 | 3.9 |
| 3 | 210 | 25.8 | 43 | 3.6 |
| 4 | 228 | 28.0 | 180 | 15.2 |
| 5 (wealthiest) | 195 | 24.0 | 895 | 75.5 |
NOTE: Descriptive statistics do not account for clustering at the facility level.
Other short‐term (ST) methods include male condom in Pakistan and male condom, female condom, and emergency contraception in Uganda.
Figure 1Percent of clients who reported being given information and percent of specific responses consistent with their method
NOTE: Vertical line represents 95 percent confidence interval for the estimate.
Figure 2Unadjusted and adjusted Method Information Index scores
NOTE: Vertical line represents 95 percent confidence interval for the estimate.
Method Information Index Scores: Unadjusted and adjusted for consistency of responses by family planning method
| Unadjusted | Adjusted for the presence of any concordant response | Adjusted for the absence of discordant responses | |
|---|---|---|---|
|
| |||
| IUD | 73.4 | 65.7 | 18.9 |
| (n = 350) | (65.2–80.3) | (57.3–73.2) | (13.7–25.4) |
| injectable | 72.4 | 68.8 | 60.8 |
| (n = 199) | (61.3–81.2) | (57.2–78.5) | (49.8–70.8) |
| Pill | 59.7 | 57.1 | 36.2 |
| (n = 149) | (46.2–71.9) | (43.8–69.4) | (25.8–48.2) |
| Male condom | 30.4 | 6.1 | 3.5 |
| (n = 115) | (18.4–45.9) | (2.9–12.5) | (1.3–9.0) |
|
|
|
|
|
|
|
|
|
|
|
| |||
| IUD | 79.4 | 58.7 | 29.7 |
| (n = 284) | (67.7–87.6) | (45.8–70.5) | (20.0–41.7) |
| Implant | 69.4 | 66.4 | 65.2 |
| (n = 424) | (58.6–78.4) | (56.1–75.3) | (54.9–74.2) |
| Injectable | 73.1 | 71.0 | 56.1 |
| (n = 337) | (61.3–82.4) | (59.4–80.5) | (43.2–68.3) |
| Pill | 71.3 | 61.5 | 38.5 |
| (n = 120) | (56.5–82.7) | (47.3–73.9) | (23.4–56.2) |
| Other ST method | 57.1 | 0.0 | 0.0 |
| (n = 22) | (37.5–74.8) | ||
|
|
|
|
|
|
|
|
|
|
NOTE: Estimates account for clustering at the facility level.
Calculated from raw reported responses.
Calculated from responses adjusted for consistency (presence of any concordant response) between specific responses and FP method received.
Calculated from responses adjusted for consistency (absence of discordant responses) between specific responses and FP method received.
Pakistan: McNemar test comparing raw and adjusted (presence of any concordant response) proportions scoring 3: difference = 8.1 (95% CI: 5.3‐10.9), p‐value < 0.001. McNemar test comparing raw and adjusted (absence of discordant responses) proportions scoring 3: difference = 34.4 (95% CI: 28.4‐40.5), p‐value < 0.001.
Uganda: McNemar test comparing raw and adjusted (presence of any concordant response) proportions scoring 3: difference = 8.5 (95% CI: 5.7‐11.4), p‐value < 0.001. McNemar test comparing raw and adjusted (absence of discordant responses) proportions scoring 3: difference = 22.3 (95% CI: 15.3‐29.3), p‐value < 0.001.
Other short‐term (ST) methods include male/female condom and emergency contraception.